🇺🇸 FDA
Patent

US 11390861

CRISPR/cas-related methods and compositions for treating herpes simplex virus

granted A61PA61P31/22

Quick answer

US patent 11390861 (CRISPR/cas-related methods and compositions for treating herpes simplex virus) held by Editas Medicine, Inc. expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Editas Medicine, Inc.
Grant date
Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61P, A61P31/22